Ovarian fibroma is the most common sex cord stromal tumour of ovary accounting to 1-5% of all ovarian tumours. Minor sex cord elements in ovarian fibroma are a rare entity occupying less than 10% of tumour area. To the best of our knowledge only 20 cases has been reported till date. This case is presented because of its rarity. Authors reported a case of fibrothecoma with minor sex cord elements in a 70yr old postmenopausal women who presented with postmenopausal bleeding with abdominal mass.
Congenital High Airway Obstruction Syndrome or CHAOS is a blockage of the foetus’s trachea or larynx due to many factors including narrowing of the airway, a web-like membrane or even tracheal atresia. In the uterus, the foetal lungs constantly produce fluid and as a result of this airway blockage in the trachea, the lung fluid cannot escape out of the foetal mouth. Because of this the foetus’s lungs become distended with fluid and over distended lungs can put pressure on the heart and affect the heart’s ability to function. If the heart cannot function effectively hydrops or congestive heart failure can occur. We present a rare case of CHAOS diagnosed prenatally at about 23 weeks by USG in our hospital.
Metastasis to uterus from extragenital site is very rare. Breast cancer is the most frequent primary tumour metastatizing to uterine corpus with incidence being 47%. We report a case of metastatic carcinomatous deposit in uterus in 56yr old postmenopausal woman who underwent modified radical mastectomy for carcinoma right breast 7yrs ago, and diagnosed to have infiltrating ductal carcinoma, now presented with history of white discharge per vaginum. Ultrasonogram revealed an endometrial polyp. Since the patient was on tamoxifen, suspecting a tamoxifen induced endometrial polyp hysterectomy was done. Histopathology revealed a benign endometrial polyp with extensive carcinomatous deposit in myometrium from breast carcinoma which was confirmed with immunohistochemistry. This case is being presented for its rarity of occurrence and to differentiate these tumours from primary epitheloid tumours of uterus.
A monoclonal antibody (25.5) has been produced that recognises luminal epithelial cells of the rat mammary gland. This antibody together with monoclonal anti-CALLA antibodies, which react with mammary myoepithelial cells, has been used in biochemical, immunocytochemical and flow cytometric studies. Antibody 25.5 bound to proteins of molecular weight 70K and 25K (K = 10(3) Mr) in both the rat milk fat globule membrane and in single cell suspensions prepared from the virgin adult rat mammary gland. Anti-CALLA antibody (J5), recognised a 93–100K protein in the gland extracts, which co-electrophoresed with the CALLA/CD-10 antigen from NALM-6 acute lymphoblastic leukaemia cell line. Antibody 25.5 bound to the luminal surface of rat mammary epithelial cells at all stages of development from neonatal through to pregnancy, lactation and involution. CALLA immunoreactive staining has previously been shown on basally located presumptive myoepithelial cells at all stages of development. Flow cytometric analyses demonstrated that 25.5 and anti-CALLA antibodies stained independent cell populations in suspensions of single cells prepared from purified epithelial elements from the mammary gland of adult virgin rat.
Background: The most common cause of morbidity & mortality among females are due to cancers
arising from female reproductive organs next to breast cancers. The most common sites include uterine
cervix, corpus uteri & ovary followed by least common sites like vulva, vagina, fallopian tubes and gestational trophoblastic
diseases.
Aim of the study:
1. To evaluate the trend in the prole of benign, premalignant & malignant lesions of female genital tract (FGT) tumours at
primary tertiary care hospital in Chennai.
2. To study frequency, age distribution & diverse histomorphological spectrum of tumours of female genital tract.
3. To compare and analyze our data with other published studies in the literature.
Materials & Methods:
This cross sectional retrospective observational study was conducted at tertiary care gynaecological center at Chennai over a
period of 12 years from Jan 2008 to Dec 2019. The medical records were retrieved, data analyzed and the results were expressed
in descriptive statistics. Results: During the study period we received 44752 histopathological specimens out of which 12477
cases were gynaecological malignancies. Cervix uteri (66.38%) was the most common site followed by ovary (16.65%), corpus
uteri (10.71%), gestational trophoblastic disease (4.13%), vulva (0.82%), vagina (0.36%), fallopian tube (0.02%), and vault
carcinoma (0.93%). Squamous cell carcinomas were most common type of malignancy in cervix (93.15%), vulva (91%), vagina
(82%) & vault (78%). Endometrial adenocarcinomas (81%) were more frequent tumour in corpus uteri while surface epithelial
tumours constitute 78.72% of cases in ovary. For gestational trophoblastic disease, 78.25% of cases had complete molar
pregnancy. 41-50yrs of age groups were commonly affected for cervical, ovarian & endometrial malignancies where as in
vulval lesions the most common age group was 61-70yrs. In case of gestational trophoblastic disease the majority of patients
were presented at 21-30yrs of age. Conclusion: This is one of the largest studies conducted with more than 10000 cases being
reported in female genital tract. Cervical carcinomas are the leading gynecological malignancy followed by ovary & corpus
uteri at our institute. There is a declining trend in the distribution of cases among cervical cancers were as there is an increasing
trend in distribution of cases in other site like ovary & corpus uteri.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.